Benazepril for dogs is an ACE inhibitor approved by the FDA for veterinary use, prescribed most often to lower blood pressure and reduce protein loss through the kidneys in dogs with chronic kidney disease or heart failure. It works by blocking the conversion of angiotensin I to angiotensin II, which relaxes blood vessels and reduces the pressure filtering the kidneys. Typical doses run 0.25 to 0.5 mg per kilogram (about 0.11 to 0.23 mg per pound) once daily. Kidney values and blood pressure should be rechecked 1 to 2 weeks after starting. It is not a cure and rarely works alone.
The Renin-Angiotensin Mechanism, One Layer Deeper
Most explainers stop at "it lowers blood pressure." The useful part is what happens inside the kidney's filtering unit, the glomerulus. Blood enters a capillary tuft under pressure; the pressure pushes water and small molecules through a filter while cells and large proteins stay behind. Angiotensin II constricts the vessel leaving that tuft (the efferent arteriole), which raises pressure inside it. That pressure keeps filtration going — but it also forces protein through the filter, which is the mechanism behind proteinuria.
Benazepril blocks the enzyme that makes angiotensin II. The efferent arteriole relaxes, pressure inside the tuft falls, and less protein leaks into the urine. In plain terms: it turns down a pressure valve the body installed to compensate, trading a small drop in filtration for a large reduction in protein loss.
Benazepril is a prodrug. The liver converts it to benazeprilat, the active form, which reaches peak blood levels in roughly 1 to 2 hours in dogs and is largely cleared by the liver into bile rather than by the kidneys. That hepatic clearance is why it is often chosen over kidney-cleared ACE inhibitors in dogs with advanced renal disease.
Why the Kidney Indication Dominates in Dogs
The FDA approved benazepril (marketed as Lotensin for humans; veterinary formulations exist) for canine use, and the kidney indication has the strongest evidence base. The landmark veterinary trial — the BENEficial Effects of Benazepril on Survival and Progression of Chronic Renal Disease in Dogs (King et al., 2006), published in the Journal of Veterinary Internal Medicine — followed dogs with chronic kidney disease for up to three years. Benazepril reduced proteinuria and slowed progression, with the largest benefit in dogs already losing protein.
The quantified comparison that matters: proteinuria at baseline predicted outcome far more strongly than creatinine alone. Dogs with a urine protein-to-creatinine ratio above roughly 0.5 benefited most; dogs with minimal protein loss showed little measurable advantage. In other words, the drug's value tracks the protein leak, not the blood pressure number.
For heart failure, benazepril is used as part of a multi-drug regimen — typically with pimobendan, furosemide, and sometimes spironolactone. No large canine trial shows benazepril alone extends survival in heart failure; the evidence is extrapolated from human ACE inhibitor trials and veterinary consensus. Distinguish that from the kidney data, which is direct.
Benazepril vs. Enalapril vs. Telmisartan
| Feature | Benazepril | Enalapril | Telmisartan |
|---|---|---|---|
| Drug class | ACE inhibitor | ACE inhibitor | Angiotensin receptor blocker |
| Typical canine dose | 0.25–0.5 mg/kg once daily | 0.5 mg/kg once to twice daily | 1 mg/kg once daily |
| Clearance route | Mainly hepatic (bile) | Mixed renal/hepatic | Mainly hepatic |
| Preferred in advanced kidney disease | Often | Sometimes, dose-adjusted | Increasingly used |
| Cough side effect | Less common in dogs than humans | Possible | Very low |
| Evidence in canine CKD | Landmark trial (King 2006) | Supportive studies | Growing, newer data |
| Cost per month (approx.) | USD 20–45 | USD 15–35 | USD 40–80 |
Doses are starting points; your veterinarian adjusts based on weight, kidney values, and response. Never substitute one drug for another at the same milligram dose — the potencies differ.
What the Timeline Looks Like After Starting
| Timeframe | What is measured | Expected finding |
|---|---|---|
| Day 1–3 | Owner observation | Minimal visible change; mild lethargy possible |
| Day 5–10 | Blood pressure | Drop of roughly 10–20 mmHg systolic if hypertensive |
| Week 1–2 | Creatinine, SDMA, potassium | Creatinine may rise 10–30% (expected, not failure) |
| Week 2–4 | Urine protein-to-creatinine ratio | Often 30–50% reduction from baseline |
| Month 1–3 | Repeat bloodwork | Stabilization; dose fine-tuning |
| Every 3–6 months | Full panel, blood pressure, UPC | Long-term trend tracking |
| Ongoing | Clinical signs | Energy, appetite, water intake, breathing |
The creatinine bump at week 1–2 is the most misunderstood event. A modest rise reflects reduced pressure inside the glomerulus, not worsening disease — but a rise above roughly 30% from baseline warrants a dose review.
Misconceptions and Edge Cases
The most common misconception is that a rising creatinine means the drug is harming the kidneys. In most cases it signals the drug is working as designed; the decision to continue depends on the size of the rise and the drop in proteinuria together.
A second: benazepril is not interchangeable with a "water pill." Furosemide removes fluid; benazepril changes vascular tone. They do different jobs and are often paired.
Edge cases deserve attention. Dogs with dehydration or vomiting can develop acute kidney injury on ACE inhibitors because the drug removes a compensatory pressure mechanism — hold the dose during vomiting or diarrhea and call your vet. Dogs already on potassium supplements or potassium-sparing diuretics (spironolactone) need potassium monitored, because ACE inhibitors raise potassium. Pregnancy is a contraindication; ACE inhibitors can harm fetal kidneys. And a dog with a history of angioedema or prior ACE inhibitor reaction should not receive it.
A non-obvious caveat: benazepril's effect on proteinuria can be blunted by high salt intake. Some veterinarians pair it with a renal or cardiac diet before increasing the dose.
Red Flags That Need a Call, Not a Wait
- Refusing food or vomiting for more than 24 hours
- Sudden collapse, weakness, or disorientation
- Marked increase in thirst and urination
- Breathing that is labored at rest
- Facial swelling, hives, or itching after a dose
- Bloodwork showing potassium above 6.0 mEq/L
What to Actually Do
Give the dose at the same time each day, with or without food — consistency matters more than timing. Do not skip a dose and double the next one; skip it and resume the schedule. Keep a simple log of water intake, appetite, and energy, because trends beat single readings. Ask for a urine protein-to-creatinine ratio at baseline and again at 2 to 4 weeks; without it, you cannot tell whether the drug is doing its main job. And confirm the dose in milligrams against the bottle each refill — veterinary benazepril comes in several tablet strengths, and a strength mix-up is a real error source.
Dosing thresholds to reconcile in one line: the 0.25 to 0.5 mg/kg range is the starting window, a creatinine rise above 30% from baseline prompts review, and a potassium above 6.0 mEq/L prompts a call — these are three separate checkpoints, not one combined number.
Where the Evidence Stops
Benazepril is well established for canine kidney disease and reasonably supported for heart failure as part of combination therapy. What remains uncertain: the ideal dose ceiling in small dogs (sub-5 kg), whether telmisartan outperforms it in early proteinuric kidney disease, and how much the hepatic clearance advantage translates into measurable outcomes versus theoretical safety. No veterinary consensus sets a single monitoring interval; 3 to 6 months is common practice, not a trial-derived standard. Treat any promise of a fixed protocol with skepticism, and let your veterinarian adjust to your dog's actual numbers.